| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 741.86 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
As doenças genéticas relacionadas com o metabolismo dos neurotransmissores
são um grupo de doenças neurometabólicas em
expansão. Neste artigo fazemos a revisão da análise de biomarcadores
no líquido cefalorraquidiano (LCR) para o diagnóstico de Doenças
Hereditárias dos Neurotransmissores (DHN). Fez-se um levantamento
retrospetivo dos doentes submetidos a análise bioquímica
dos neurotransmissores (NT), por apresentarem suspeita de DHN,
com uma variabilidade de apresentações neurológicas e com idades
que variavam entre a idade neonatal, pediátrica e adulta. O estudo
foi efetuado no laboratório de Bioquímica Genética/Endocrinologia
Especial do Hospital Dona Estefânia (HDE), CHULC, Lisboa, num
período compreendido entre 2015-2021. Dos 277 casos levantados
107 (38,6%) apresentavam concentração de metabolitos dentro dos
valores de referência. Dos restantes 170 pacientes que apresentavam
alterações, três (1,08%) apresentaram um perfil bioquímico
compatível com défice primário dos NT, confirmado por diagnóstico
molecular; em 165 dos casos (59,6%) concluiu-se que a s alterações
dos metabolitos estavam relacionadas com alterações secundárias.
Os restantes dois casos (0,72%) correspondiam a distonias sensíveis
à dopa, e permaneceram sem confirmação molecular. Tentamos
explorar a correlação de alterações secundárias dos neurotransmissores
major com as manifestações clínicas. Com este trabalho preliminar
pretendemos divulgar e evidenciar a importância destes diagnósticos,
que permitem excluir alterações primárias de secundárias
e, ainda, partilhar a experiência e a casuística que servirá de base a
um futuro artigo de investigação mais completo.
Genetic alterations related to neurotransmitter metabolism are an expanding group of neurometabolic diseases. In this article, we review the analysis of biomarkers in cerebrospinal fluids (CSF) for the diagnosis of Hereditary Neurotransmitter Disorders (HND). A retrospective survey was carried out on patients submitted to biochemical analysis of neurotransmitters, due to suspicion of HDN, with variable neurological presentations, and ages ranging from neonatal, to pediatric and adult. The study was carried out at the Laboratory of Biochemical Genetics/Special Endocrinology at the Hospital Dona Estefania (HDE), Lisbon, between 2015-2021. Of the 277 cases surveyed, 107 (38.6%) had concentrations of metabolites within the reference values. Of the remaining 170 patients with alterations, 3 cases (1.08%) had a biochemical profile compatible with a primary deficit with confirmed molecular diagnosis, 165 cases (59.6%) were considered related to secondary alterations, and the remaining 2 cases (0.72%) corresponding to dopa-reponsive dystonias, remained without molecular confirmation. We attempted to explore the correlation of minor changes in major neurotransmitters with clinical manifestations. With this preliminary article, we intend to disseminate and highlight the importance of these diagnoses, which allow excluding primary and secondary alterations, as well as to share the experience and reasoning, serving as a b asis for ongoing research.
Genetic alterations related to neurotransmitter metabolism are an expanding group of neurometabolic diseases. In this article, we review the analysis of biomarkers in cerebrospinal fluids (CSF) for the diagnosis of Hereditary Neurotransmitter Disorders (HND). A retrospective survey was carried out on patients submitted to biochemical analysis of neurotransmitters, due to suspicion of HDN, with variable neurological presentations, and ages ranging from neonatal, to pediatric and adult. The study was carried out at the Laboratory of Biochemical Genetics/Special Endocrinology at the Hospital Dona Estefania (HDE), Lisbon, between 2015-2021. Of the 277 cases surveyed, 107 (38.6%) had concentrations of metabolites within the reference values. Of the remaining 170 patients with alterations, 3 cases (1.08%) had a biochemical profile compatible with a primary deficit with confirmed molecular diagnosis, 165 cases (59.6%) were considered related to secondary alterations, and the remaining 2 cases (0.72%) corresponding to dopa-reponsive dystonias, remained without molecular confirmation. We attempted to explore the correlation of minor changes in major neurotransmitters with clinical manifestations. With this preliminary article, we intend to disseminate and highlight the importance of these diagnoses, which allow excluding primary and secondary alterations, as well as to share the experience and reasoning, serving as a b asis for ongoing research.
Description
Keywords
Líquido Cefalorraquidiano Doenças Hereditárias dos Neurotransmissores Diagnóstico Doenças Genéticas e Hereditárias Doenças Genéticas
Pedagogical Context
Citation
Boletim Epidemiológico Observações. 2023 janeiro-abril;12(33):21-26
Publisher
Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
